This study for the first time has revealed that NDRG2 expression can be down-regulated in patients with CLL, and that NDRG2 mRNA levels may be a useful prognostic variable in CLL patients. This evidence concerns the gene NDRG2 and B-cell chronic lymphocytic leukemia.